Clinical Trials

Clinical Trial Detail

Return to search results.

Alpha 1 Anti-Trypsin in Treating Patients With Acute Graft-Versus-Host Disease

Complete title: Treatment of Steroid Non-responsive Acute GVHD with Alpha 1 Anti-trypsin (AAT). A Phase I/II Study

Research Study Number       2571.00
Principal Investigator       Joachim Deeg, MD
Phase       I/II

Look up trial at NIH

Research Study Description

This phase I/II trial studies the side effects and best dose of alpha 1 anti-trypsin (alpha-1-proteinase inhibitor human) and to see how well it works in treating patients with acute graft-versus-host disease (GVHD). Alpha-1-proteinase inhibitor human may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Patients transplanted from related or unrelated, human leukocyte antigen (HLA)-matched or mismatched donors

- Patients transplanted with hematopoietic stem cells from any source

- Patients receiving calcineurin inhibitors as part of GVHD prophylaxis

- Patients with acute GVHD grades II-IV developing despite GVHD prophylaxis

- Patients who have not shown a satisfactory response to methylprednisolone-equivalent doses at 2 mg/kg/day; the weight used to dose methylprednisolone can be actual, adjusted or ideal body weight

- Signed and dated informed consent

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients who have received any systemic agents in addition to steroids for treatment of GVHD

- Patients unable to give informed consent

- Patients with manifestations of classic chronic GVHD

- Patients with evidence of recurrent malignancy

- Patients with acute/chronic GVHD overlap syndrome

- Patients whose GVHD developed after donor lymphocyte infusion (DLI)

- Patients with severe organ dysfunction

- * On dialysis

- * Requiring oxygen (O2) at more than 2 l/min

- * Uncontrolled arrhythmia or heart failure

- * Veno-occlusive disease (sinusoidal obstruction syndrome)

- Patients with uncontrolled infections

Other exclusion criteria may apply.

Research Study Number       2571.00
Contact       Seattle Cancer Care Alliance Intake Office
Telephone       800-804-8824 / 206-288-1024

Hematologic Malignancies; Immunodeficiency Syndromes

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.